Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, secured CHF40 million in the first close of Series D funding led by EGS Beteiligungen AG. The company plans to use the funding to strengthen its growing portfolio offering in spatial biology as well as support commercial execution to address ever-growing demand from customers.
Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues. The technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials. Its COMET products line is the only fully automated, high-throughput, hyperplex platform with superior tissue profiling capabilities.
COMET is currently adopted by the world’s leading research institutions and has been a growth driver for Lunaphore, where COMET sales grew more than 350% over 2022. The measured pull-through is best-in-class among existing comparables.
Ata Tuna Ciftlik, CEO of Lunaphore commented, “The funding comes in a meaningful time where we are experiencing excellent traction over the last 12 months since the first launch of our COMET product line, and we are very proud to see the world’s best institutions and blue-chip pharma companies among our customers.”
The round was led by Ernst-Göhner Stiftung Beteiligungen (EGSB), and existing investors PHC Holdings Corporation, Swiss Entrepreneurs Fund, OCCIDENT, and Redalpine participated. The funding includes a EUR 10M venture debt facility provided by Norgine Ventures.
“We are thrilled to have such a highly regarded name like EGSB among our investors. EGSB has an excellent track record of supporting rapidly growing portfolio companies beyond $100M in revenues. In addition, the debt facility from Norgine Ventures will help us to invest in scaling our company even faster,” said Ciftlik.
EGS Beteiligungen AG is the investment arm of the Ernst Göhner Foundation. EGSB invests with a long-term horizon into established and growth-stage companies based in Switzerland and pursuing global ambitions. Amongst others, EGSB is invested in Sensirion, Spineart, and Beekeeper.
“Cutting edge technology enabling the next frontier in biology & medicine – that is Lunaphore,” summarizes Dominik Sauter, Managing Director of EGS Beteiligungen AG the investment. “Lunaphore is at an inflection point of its trajectory, and we are thrilled to support the leadership team around CEO Ata Tuna Ciftlik in executing on their vision” added Dominik Sauter.
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines